Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Availability and Affordability of Essential Medicines and Diagnostic Tests for Diabetes Mellitus and Cardiovascular Diseases in Sub-Saharan Africa: A Systematic Review
29 Pages Posted: 7 Oct 2018
More...Abstract
Background: Diabetes mellitus (DM) and cardiovascular diseases (CVD) pose a significant health challenge in sub-Saharan Africa (SSA). Interventions to improve access to affordable essential medicines and diagnostic tests are needed to reduce morbidity and mortality due to these conditions. We performed this systematic review to evaluate the availability and affordability of essential medicines and diagnostic tests for DM and CVD in SSA, where health resources are particularly scarce.
Methods: PubMed, Scopus and African Journal Online databases were searched for original research articles conducted in SSA between 2000 and March 2018 with information about availability and affordability of essential medicines and diagnostic tests for DM and CVD.
Findings: Twenty cross sectional studies were identified with the majority performed in East African countries (n=12, 60%). Availability of insulin and oral hypoglycaemic agents (OHA) widely ranged from 0-100%. Angiotensin converting enzyme inhibitors, anti-platelet drugs and statins were available in 0-96.5%, 20.8-100% and 3.1-84% of surveyed health facilities respectively. Availability of blood glucose testing, glycated haemoglobin (HbA1c), electrocardiography (ECG) and troponin testing ranged from 6-100%, 20-43.5%, 9.1-81.8% and 0-43.2% respectively. The monthly cost of the majority of the lowest priced generic medicines and diagnostic tests was <3.5 days' wages. The cost of insulin, statins and unfractionated heparin widely ranged from 3.85-18.7 days' wages, 6.5-30.51 days' wages and 38.5-182.36 days' wages respectively.
Interpretation: The availability and affordability of essential medicines and diagnostic tests for DM and CVD in SSA is suboptimal. Pragmatic solutions are urgently needed to address this challenge.
Funding Statement: The authors declare: "No funding was received for this work."
Declaration of Interests: The authors declare no competing interests.
Keywords: availability, affordability, essential medicines, diagnostic tests, diabetes mellitus, cardiovascular diseases, sub-Saharan Africa, Africa
Suggested Citation: Suggested Citation